# DIG-HIF-1 Pharmacodynamic Trial in Newly Diagnosed Operable Breast Cancer

> **NCT01763931** · PHASE2 · COMPLETED · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins** · enrollment: 6 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Digoxin

## Key facts

- **NCT ID:** NCT01763931
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-01
- **Primary completion:** 2016-04-01
- **Final completion:** 2016-04-01
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2020-01-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01763931

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01763931, "DIG-HIF-1 Pharmacodynamic Trial in Newly Diagnosed Operable Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01763931. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*